To provide biomarkers having clinical relation with cytokine release syndrome (CRS).SOLUTION: The disclosure herein is, at least in part, a discovery that some biomarkers are able to accurately predict CRS at immune cell based treatment, i.e., an early stage during CAR T cell processing (before a subject becomes severely ill from CRS, within 10, 9, 8, 7, 6, 5, 4, 3, 2 or 1 day(s) from a first dosage of a CAR T cell, or lesser). Two cytokines, sgp130 and IFNγ, are strongly associated with an onset of severe CRS. In adult and pediatric subjects, accurate early prediction of severe CRS was able to be made using IFN, sgp130, and IL-1Ra. In the pediatric subjects, the accurate early prediction of severe CRS was able to be made using IFNγ, IL13, and MIP1α; or using assessment of sgp130, IFNγ, and disease burden.SELECTED DRAWING: None
BIOMARKERS PREDICTIVE OF CYTOKINE RELEASE SYNDROME